MET and renal cell carcinoma: In a phase II trial of cabozantinib that targets MET, AXL, and VEGFR2 plus nivolumab, a human PD-1 blocking antibody, NF2 GA were found in 19% of unclassified/papillary, and translocation-associated RCC (6).